IRIS Institutional Research Information System - OPENBS Open Archive UniBS

BELLUCCI, ARIANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.733
EU - Europa 4.508
AS - Asia 3.867
SA - Sud America 659
Continente sconosciuto - Info sul continente non disponibili 393
AF - Africa 101
OC - Oceania 13
Totale 17.274
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.506
PL - Polonia 1.629
SG - Singapore 1.281
CN - Cina 1.263
IT - Italia 682
UA - Ucraina 573
BR - Brasile 546
DE - Germania 440
HK - Hong Kong 407
VN - Vietnam 301
FI - Finlandia 272
FR - Francia 223
GB - Regno Unito 210
RU - Federazione Russa 135
TR - Turchia 129
IN - India 127
IE - Irlanda 110
CA - Canada 101
BD - Bangladesh 99
MX - Messico 42
ID - Indonesia 38
NL - Olanda 36
SE - Svezia 36
IQ - Iraq 34
AR - Argentina 32
KR - Corea 30
ZA - Sudafrica 29
BE - Belgio 26
CZ - Repubblica Ceca 26
JP - Giappone 26
ES - Italia 23
CR - Costa Rica 20
EC - Ecuador 19
PK - Pakistan 19
AT - Austria 17
CO - Colombia 16
IL - Israele 16
VE - Venezuela 15
KE - Kenya 13
AU - Australia 12
UZ - Uzbekistan 12
NG - Nigeria 11
CH - Svizzera 10
HN - Honduras 10
JO - Giordania 10
AZ - Azerbaigian 9
EG - Egitto 9
GT - Guatemala 9
MA - Marocco 9
NI - Nicaragua 9
PY - Paraguay 9
PE - Perù 8
BG - Bulgaria 7
KZ - Kazakistan 7
LT - Lituania 7
SK - Slovacchia (Repubblica Slovacca) 7
TN - Tunisia 7
TT - Trinidad e Tobago 7
AE - Emirati Arabi Uniti 6
IR - Iran 6
JM - Giamaica 6
BY - Bielorussia 5
CL - Cile 5
DZ - Algeria 5
EE - Estonia 5
ET - Etiopia 5
EU - Europa 5
MY - Malesia 5
PT - Portogallo 5
SA - Arabia Saudita 5
BB - Barbados 4
BO - Bolivia 4
DK - Danimarca 4
SV - El Salvador 4
UY - Uruguay 4
AM - Armenia 3
CW - ???statistics.table.value.countryCode.CW??? 3
DO - Repubblica Dominicana 3
GP - Guadalupe 3
GR - Grecia 3
HU - Ungheria 3
LA - Repubblica Popolare Democratica del Laos 3
LV - Lettonia 3
MU - Mauritius 3
NP - Nepal 3
OM - Oman 3
PH - Filippine 3
PR - Porto Rico 3
PS - Palestinian Territory 3
RO - Romania 3
SC - Seychelles 3
AL - Albania 2
BH - Bahrain 2
CY - Cipro 2
HR - Croazia 2
KG - Kirghizistan 2
LB - Libano 2
MM - Myanmar 2
PA - Panama 2
SN - Senegal 2
Totale 16.865
Salva come PNG Salva come JPEG
Città #
Warsaw 1.624
Ashburn 756
Singapore 699
Fairfield 561
Woodbridge 427
Jacksonville 423
San Jose 422
Hong Kong 406
Chandler 292
Beijing 271
Dearborn 270
Houston 253
Cambridge 246
Council Bluffs 237
Seattle 227
Brescia 225
The Dalles 223
Ann Arbor 207
Wilmington 202
Princeton 192
Helsinki 180
New York 177
Nanjing 145
Los Angeles 124
Dublin 109
Munich 103
Lauterbourg 100
Istanbul 97
Ho Chi Minh City 84
Columbus 83
Milan 81
Dallas 78
Dong Ket 66
Santa Clara 66
São Paulo 62
Des Moines 58
Chicago 55
Buffalo 54
San Francisco 53
Jinan 50
Moscow 48
Nanchang 48
Shanghai 47
Hanoi 45
Changsha 43
Hebei 40
Shenyang 39
Pune 38
Orem 36
Toronto 35
Boardman 34
North Bergen 34
Tianjin 34
Denver 33
San Diego 33
Redondo Beach 31
London 29
Phoenix 29
Atlanta 28
Jakarta 28
Rome 27
Turku 27
Brussels 25
Frankfurt am Main 25
Tokyo 24
Kunming 23
Brooklyn 20
Rio de Janeiro 20
Hangzhou 19
Brno 18
Guangzhou 18
Jiaxing 18
Nuremberg 18
Ningbo 17
San José 17
Poplar 16
Taizhou 16
Lappeenranta 15
Montreal 15
Stockholm 14
Tucson 14
Zhengzhou 14
Ankara 13
Baghdad 13
Brasília 13
Manchester 13
Nairobi 13
Newark 13
San Giuliano Milanese 13
Boston 12
Haiphong 12
Johannesburg 12
Paris 12
Tashkent 12
Verona 12
Belo Horizonte 11
Dhaka 11
Hefei 11
Lanzhou 11
Mexico City 11
Totale 11.358
Salva come PNG Salva come JPEG
Nome #
Anionic liposomes for siRNA delivery to primary neuronal cells: evaluation of Alpha synuclein knockdown efficacy 399
Neuroprotective and Anti-Apoptotic Effects of CSP-1103 in Primary Cortical Neurons Exposed to Oxygen and Glucose Deprivation 384
Redistribution of DAT/α-synuclein complexes visualized by “in situ” proximity ligation assay in transgenic mice modelling early Parkinson’s disease 332
Dopamine transporter/α-synuclein complexes are altered in the post mortem caudate putamen of Parkinson’s disease: An in situ proximity ligation assay study 309
NF-κB in Innate Neuroprotection and Age-Related Neurodegenerative Diseases 302
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice. 293
INDUCTION OF INFLAMMATORY MEDIATORS AND MICROGLIAL ACTIVATION IN MICE TRANSGENIC FOR MUTANT P301S TAU PROTEIN 282
Mild inflammatory profile without gliosis in the c-rel deficient mouse modeling a late-onset parkinsonism 277
The End Is the Beginning: Parkinson's Disease in the Light of Brain Imaging 272
The Contribution of -Synuclein Spreading to Parkinson’s Disease Synaptopathy 269
The "in situ" proximity ligation assay to probe protein-protein interactions in intact tissues 243
Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate 240
Alpha-Synuclein Preserves Mitochondrial Fusion and Function in Neuronal Cells 238
Alpha-synuclein modulates NR2B-containing NMDA receptors and decreases their levels after rotenone exposure 237
null 222
Mitochondria and alpha-synuclein: Friends or foes in the pathogenesis of Parkinson's disease? 219
NF-κB/c-Rel deficiency causes Parkinson's disease-like prodromal symptoms and progressive pathology in mice 218
Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of PD brains 213
Abiraterone acetate exerts a cytotoxic effect in human prostate cancer cell lines 212
c-Rel deficient mice, a mouse model of "spreading" PD-like pathology. 207
Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation 200
The proximity ligation assay: an high throughput technique for protein analysis in neuroscience 194
α-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons 185
From α-synuclein to synaptic dysfunctions: new insights into the pathophysiology of Parkinson's disease 183
Depletion of Progranulin Reduces GluN2B-Containing NMDA Receptor Density, Tau Phosphorylation, and Dendritic Arborization in Mouse Primary Cortical Neurons 181
c-Rel deficient mice, a mouse model of “spreading” PD-like pathology 178
Point mutated Caveolin-3 form (P104L) impairs myoblast differentiation via Akt and p38 signalling reduction, leading to an immature cell signature 175
Mitochondrial Dysfunction and Alpha-Synuclein Synaptic Pathology in Parkinson’s Disease: Who’s on First? 174
Targeting of Disordered Proteins by Small Molecules in Neurodegenerative Diseases 174
Synapsin III alterations in Parkinson's disease 174
Involvement of Synapsin III in the onset of Alpha-synuclein pathology in Parkinson’s Disease 173
NF-κB unbalance and dysfunction in acute and age-related neurodegenerative disease 172
DIFFERENTIAL ACTIVATION OF MITOGEN-ACTIVATED PROTEIN KINASE SIGNALLING PATHWAYS IN THE HIPPOCAMPUS OF CRND8 TRANSGENIC MOUSE, A MODEL OF ALZHEIMER'S DISEASE 171
Synapsin III and Alpha-Synuclein cooperation in the onset of synaptic pathology in Parkinson’s Disease 171
ALPHA-SYNUCLEIN MODULATES SYNAPSIN III IN NIGROSTRIATAL DOPAMINERGIC NEURONS: IMPLICATIONS FOR PARKINSON'S DISEASE 169
AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons of Synapsin III knockout mice reveals novel molecular features involved in Parkinson's disease pathology. 169
Mitochondrial Dysregulation and Impaired Autophagy in iPSC-Derived Dopaminergic Neurons of Multiple System Atrophy 166
EFFECT OF SUBCHRONIC ADMINISTRATION OF METRIFONATE, RIVASTIGMINE AND DONEPEZIL ON BRAIN ACETYLCHOLINE IN AGED F344 RATS 163
Nicotine prevents alpha-synuclein accumulation in mouse and human iPSC-derived dopaminergic neurons through activation of the dopamine D3- acetylcholine nicotinic receptor heteromer 160
Involvement of Synapsin III in the onset of alpha-synuclein synaptic pathology in Parkinson’s disease 158
Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of Parkinson’s disease and dementia with Lewy bodies, 156
ABNORMAL PROCESSING OF TAU IN THE BRAIN OF AGED TGCRND8 MICE 154
Design and Synthesis of Fluorescent Methylphenidate Analogues for a FRET-Based Assay of Synapsin III Binding 153
ANALOGHI STRUTTURALI DEL METILFENIDATO COME AGENTI DISEASE-MODIFYING DELLA MALATTIA DI PARKINSON 153
SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. 151
Synapsin III Alteration in Parkinson's disease 151
Synapsin III Alteration in Parkinson's disease 150
Alpha-Synuclein in the Regulation of Brain Endothelial and Perivascular Cells: Gaps and Future Perspectives 150
PGRN gene silencing in primary neuronal cultures: a model of FTLD-U 149
Nuclear Factor-κB Dysregulation and α-Synuclein Pathology: Critical Interplay in the Pathogenesis of Parkinson’s Disease 149
A novel stable transgenic zebrafish line expressing mCherry-tagged human alpha-synuclein in the nervous system and exhibiting all the key features of Lewy body disorders at larval stage 144
An updated reappraisal of synapsins: structure, function and role in neurological and psychiatric disorders 144
Alpha-synuclein and NMDA receptors: a novel postsynaptic couple playing a pivotal role in the regulation of the functional activity of nigral dopaminergic neurons 142
Alpha-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson’s disease 142
COMBINED TREATMENT WITH ATORVASTATIN AND MINOCYCLINE SUPPRESSES SEVERITY OF EAE 141
Alpha-synuclein modulates the localization, expression and function of NR2B-containing NMDA receptors: implications in the pathogenesis of Parkinson's disease 141
Presence of Reactive Microglia and Neuroinflammatory Mediators in a Case of Frontotemporal Dementia with P301S Mutation. 140
Role of dopamine D3R and acetylcholine nicotinic receptor interaction in the regulation of dopaminergic neurons function. 138
Extracellular clusterin limits the uptake of α-synuclein fibrils by murine and human astrocytes 137
Alpha-synuclein aggregation in dopaminergic cells is modulated by glucose metabolism 135
Exploring LRRK2-dependent clearance of α-synuclein pffs in glial cells via clusterin 135
. Alpha-synuclein is a crucial mediator of mitochondrial fusion and functions 134
The good and bad of therapeutic strategies that directly target α-synuclein 132
CHOLINERGIC DYSFUNCTION, NEURONAL DAMAGE AND AXONAL LOSS IN TGCRND8 MICE 129
Role of dopamine D3R/nAChR heterodimeric complex in the regulation of dopaminergic neurons function. 129
Parkinson's disease: from synaptic loss to connectome dysfunction 127
Synapsin III knock-out reduces AAV-alpha-synuclein overexpression-related neuropathology in the nigrostriatal system 127
Study of alpha-synuclein fibrillation: State of the art and expectations 119
MicroRNA‑34a‑5p expression in the plasma and its extracellular vesicle fractions in subjects with Parkinson's disease: An exploratory study 118
NF-κB/c-Rel DNA-binding is reduced in substantia nigra and peripheral blood mononuclear cells of Parkinson's disease patients 116
Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson’s disease 116
Neuroprotective epi-drugs quench the inflammatory response and microglial/macrophage activation in a mouse model of permanent brain ischemia 115
Redistribution of DAT/alpha-synuclein complexes visualized "in situ" by proximity ligation assay in a transgenic mouse model of Parkinson's disease 112
Effects of rofecoxib treatment on brain inflammatory reaction and cholinergic function in beta-(1-42) injected rats into the nucleus basalis 112
Selective dopaminergic alpha-synuclein pathological changes following glucose deprivation "in vitro": implications for Parkinson's disease 111
Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and synaptic protein’s redistribution 111
Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson’s disease 111
Non-steroid antiinflammatory agents (nsaids): are they a valid approach to Alzheimer’s disease prevention? 109
Alpha-synuclein absence affected mitochondrial fusion and functions 109
Alpha-Synuclein is Involved in DYT1 Dystonia Striatal Synaptic Dysfunction 106
Alpha synuclein post translational modifications: potential targets for Parkinson’s disease therapy? 106
Methylphenidate Analogues as a New Class of Potential Disease-Modifying Agents for Parkinson’s Disease: Evidence from Cell Models and Alpha-Synuclein Transgenic Mice 106
Induction of the unfolded protein response by α-synuclein in experimental models of Parkinson's disease. 106
The contribution of β-amyloid, Tau and α-synuclein to blood–brain barrier damage in neurodegenerative disorders 105
THE SELECTIVE CYCLOOXIGENASE-2 INHIBITOR ROFECOXIB SUPPRESSES BRAIN INFLAMMATION AND PROTECTS CHOLINERGIC NEURONS FROM EXCITOTOXIC DEGENERATION IN VIVO 105
BETA-AMYLOID INFLAMMATION AND CHOLINERGIC HYPOFUNCTION IN THE RAT BRAIN IN VIVO: INVOLVEMENT OF P38MAPK PATHWAY 104
In vivo effects of NSAIDs on amyloid beta(1-42)-induced brain neurotoxicity 104
EXPERIMENTAL BRAIN INFLAMMATION AND NEURODEGENERATION AS MODEL OF ALZHEIMER'S DISEASE: PROTECTIVE EFFECTS OF SELECTIVE COX-2 INHIBITORS 100
Effects of novel NSAIDs on brain inflammation and release of neurotrasmitters in animal models of neurodegeneration 97
Acetylated α-Tubulin and α-Synuclein: Physiological Interplay and Contribution to α-Synuclein Oligomerization 96
Ex vivo characterization of progranulin gene silencing in primary neuronal cultures to study the biological basis of FTLD-U 96
Early α-synuclein/synapsin III co-accumulation, nigrostriatal dopaminergic synaptopathy and denervation in the MPTPp mouse model of Parkinson's Disease 95
NSAIDs in animal models of Alzheimer’s Disease 94
Induction of the unfolded protein response by alpha-synuclein in experimental models of Parkinson's disease 93
Changes in α-Synuclein Posttranslational Modifications in an AAV-Based Mouse Model of Parkinson's Disease 92
NSAIDs in Animal Models of Alzheimer's disease 92
Synapsin III gene silencing redeems alpha-synuclein transgenic mice from Parkinson's disease-like phenotype 92
Nanorod-associated plasmonic circular dichroism monitors the handedness and composition of α-synuclein fibrils from Parkinson's disease models and post-mortem brain 90
Neuroprotective effects of D2/D3 agonists in an "in vitro" model of dopaminergic degeneration 90
Synapsin III Regulates Dopaminergic Neuron Development in Vertebrates 89
Totale 16.108
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.732
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.732
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022577 0 0 0 32 9 46 33 62 34 80 92 189
2022/2023866 125 10 30 63 90 212 7 99 132 21 39 38
2023/2024967 63 20 91 60 57 177 46 50 185 20 32 166
2024/20252.168 15 36 35 257 238 156 231 103 247 158 395 297
2025/20264.507 393 511 307 689 495 398 693 168 237 364 193 59
2026/20271.318 178 162 370 608 0 0 0 0 0 0 0 0
Totale 17.274